J. Aboulker

发表

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

C. Giaquinto, A. Walker, J. Darbyshire, 2002, The Lancet.

A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: The PENTA-4 trial

C. Giaquinto, J. Darbyshire, D. Gibb, 1998 .

A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.

P. Lebon, D. Descamps, M. Gougeon, 1997, AIDS.

Activity of Ethics Committees in Europe on issues related to clinical trials in paediatrics: Results of a survey

C. Giaquinto, F. Bonifazi, A. Ceci, 2009 .

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–<36 months

C. Giaquinto, W. Snowden, Linda J Harrison, 2010, Antiviral therapy.

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome

C. Giaquinto, J. Darbyshire, A. Babiker, 2004, AIDS.

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.

C. Delaugerre, J. Molina, S. Gallien, 2015, The Journal of antimicrobial chemotherapy.

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial

É. Oksenhendler, Y. Lévy, C. Goujard, 1999, The Lancet.

Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children

M. Hughes, D. Harris, C. Giaquinto, 2010, AIDS.

Zidovudine Resensitization and Dual HIV-1 Resistance to Zidovudine and Lamivudine in the Delta Lamivudine Roll-Over Study

F. Brun-Vézinet, B. Masquelier, J. Izopet, 1998, Antiviral therapy.

Lymphoma and Epstein−Barr virus DNA in blood during interleukin‐2 therapy in antiretroviral‐naïve HIV‐1‐infected patients: a substudy of the ANRS 119 trial

Y. Lévy, J. Molina, F. Agbalika, 2014, HIV medicine.

Concorde trial of immediate versus deferred zidovudine

Bernard Hirschel, Julio S. G. Montaner, George Davey Smith, 1994, The Lancet.

Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication

C. Delaugerre, B. Marchou, J. Braun, 2012, HIV medicine.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

D. Cooper, J. Darbyshire, B. Salzberger, 2006, The Lancet.